BioMedNewsBreaks

MondayJan 06, 2020 11:05 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Biotech Showcase(TM) 2020 in San Francisco

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its plans to attend and present at the Biotech Showcase(TM) 2020, to be held at the Hilton San Francisco Union Square in San Francisco from January 13–15, 2020. Genprex’s President and COO, Julien Pham, MD, MPH, will lead its presentation, scheduled for Monday, January 13 at 11:30 a.m. PT (2:30 p.m. ET); Track: Yosemite C (Ballroom Level). In addition, Pham and the company’s CEO, Rodney Varner, will be available for one-on-one investor meetings. “We are…

Continue Reading

ThursdayNov 21, 2019 9:32 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces $1.26M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, on Wednesday announced a registered direct offering of 3,167,986 shares of its common stock at a price of $0.40 each, for gross proceeds of about $1.26 million prior to deduction of commissions and offering expenses. In a concurrent private placement, Genprex agreed to issue unregistered warrants to purchase up to 3,167,986 shares to the investors in the registered direct offering. The warrants, which have an exercise price of $0.46 per share, will be exercisable six months from the issuance date and will expire after five years. The warrants will be exercisable for…

Continue Reading

TuesdayNov 19, 2019 10:59 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Reports Preclinical Data Showing Positive Results for Treatment of Resistant Metastatic Lung Cancers

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclinical data at the American Association of Cancer Research Tumor Immunology and Immunotherapy Meeting 2019. According to the update, the data shows positive results for the combination of TUSC2 immunogene therapy with an anti-PD1 antibody, pembrolizumab, and for the combination of TUSC2 immunogene therapy, pembrolizumab, and chemotherapy for the treatment of some of the most resistant metastatic lung cancers, including the KRAS and LKB1 mutations. “These data not only further support existing preclinical data…

Continue Reading

MondayNov 04, 2019 10:58 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced that it is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness in support of November’s Lung Cancer Awareness Month. According to the update, each case is unique, but several preventative actions may lower the risk of lung cancer, including avoiding or quitting smoking, reducing exposure to secondhand smoke and radon, and knowing one’s familial history with lung cancer. Genprex is developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including its initial product candidate, Oncoprex(TM) immunogene…

Continue Reading

WednesdayOct 09, 2019 9:44 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Inaugural MicroCap Rodeo Investor Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced its plans to present at the upcoming inaugural MicroCap Rodeo Investor Conference to be held at the Hilton Austin - Downtown in Austin, Texas. Genprex’s presentation is scheduled to take place on Tuesday, October 15 at 9:10 a.m. Central Time, led by its Chairman and CEO Rodney Varner, who will also be available for one-on-one meetings with investors. In addition, the presentation will be available via live webcast, with an archived recording to be provided for later viewing. To view the full press release, visit http://nnw.fm/sISn1 About Genprex, Inc. Genprex, Inc.…

Continue Reading

MondayOct 07, 2019 10:37 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Pioneering Use of Non-Viral Vector Delivery for Gene Therapy Validated by Additional Industry Research

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced additional research in the field validating non-viral vector delivery as the next evolution in gene therapy. Per the update, a recently published paper titled, “Encapsulation, Visualization and Expression of Genes with Biomimetically Mineralized Zeolitic Imidazolate Framework-8 (ZIF-8),” by researchers in Australia, Spain and Austria, supports the belief that non-viral delivery could be a safer alternative for patients than viral vectors, also potentially speeding production time while reducing costs. Genprex was not involved in the study that used a different nanotechnology. “One of the biggest differentiators between Genprex and other gene therapy…

Continue Reading

WednesdaySep 25, 2019 10:48 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Highlighted in Editorial on Potential Breast Cancer Treatments

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its placement in an editorial published by BioMedWire ("BMW"), a multifaceted financial news and publishing company for private and public entities. The publication, titled “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers,” may be accessed via the following link: http://nnw.fm/pNKm2. The editorial reads,“‘Disruptive’ isn’t a term that’s often applied to medicine, where the aim is to avoid disrupting the health of the human body. But technology such as Genprex Inc.’s (NASDAQ: GNPX) Oncoprex(TM) immunogene therapy is disruptive precisely because it could improve doctors’ ability to preserve health. It may…

Continue Reading

WednesdaySep 18, 2019 10:22 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) CEO to Present Via Webcast at September 19 Singular Research Midwestern Values Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will present, via webcast, at the Singular Research Midwestern Values Conference on September 19, 2019. Genprex Chairman and CEO Rodney Varner will lead the company's webcast presentation. The presentation is scheduled to begin at 4:00 PM Central Time, and interested parties may register for the webcast via the Singular Research website. To view the full press release, visit http://nnw.fm/IxlP7 About Genprex, Inc. Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial…

Continue Reading

WednesdaySep 11, 2019 10:17 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) TUSC2 Found to Prevent Tumor Growth in Triple-Negative Breast Cancer by Independent Researchers

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that non-affiliated, independent researchers have reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, prevented tumor growth in triple-negative breast cancer (“TNBC”). Currently considered an incurable cancer, there are limited therapeutic options available for TNBC. “The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging,” Genprex Chairman and CEO Rodney Varner said in the news release. “We believe that the data reported in this Nature article by independent researchers supports our belief that…

Continue Reading

ThursdaySep 05, 2019 9:19 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Corporate Update; Set to Present at H.C. Wainwright 21st Annual Global Investment Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update regarding its clinical development programs, manufacturing and strategy for bringing its Oncoprex(TM) immunogene therapy to market. A corporate presentation is available on GNPX’s website which details anticipated milestones and future guidance for the company. “These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most,” Genprex chairman and chief executive officer Rodney Varner stated in the news release. “We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we believe that achievement of these milestones…

Continue Reading